Search

everythinglearnresearchcommunity

for

Search:↓

The study found that certain microRNAs are higher in the cells and lower in the fluid of women with a specific type of polycystic ovary syndrome, and one microRNA could potentially help diagnose the condition.

The conclusion suggests that PCOS may persist due to genetic traits that, while harmful for female fertility, could have provided survival and reproductive benefits to males.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

We need better ways to test and understand SARMs to make safer and more effective treatments.

Hormone therapy is safe and effective for transgender adults, but requires regular monitoring and mental health support.

PCOS involves hormonal and metabolic issues, increasing risks for diabetes and heart disease, and requires lifestyle changes and medication for management.

Combining antidiabetic drugs, hormonal therapies, and lifestyle changes can improve health in women with PCOS.

Sex hormones likely did not affect COVID-19 outcomes in South Korea.

Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.

Acne is caused by genetics, diet, hormones, and bacteria, with treatments not yet curative.

Men are more likely to get infectious skin diseases, while women are more prone to autoimmune and pigment-related skin conditions, influenced by biological and environmental factors.

Betacoronaviruses, like COVID-19, may cause hormone system dysfunction and affect disease susceptibility and severity.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

Most skin changes during pregnancy are harmless and moles don't significantly change, but many women experience pigmentation changes due to hormones and sun exposure.

Certain skin conditions in women are linked to higher risks of metabolic syndrome and type 2 diabetes due to hormone imbalances.

Bisphenol-A (BPA) increases connections between brain cells and boosts their activity, but it blocks the effects of a male hormone on brain cell plasticity.

A hormone linked to collagen helps hair grow back in mice after chemotherapy, and may also prevent bone loss.

Skin problems in PCOS, like excess hair, acne, and hair loss, may not always indicate high male hormone levels and need careful diagnosis for proper treatment.

Female pattern hair loss diagnosis is challenging and should use dermoscopy and histopathology instead of pattern recognition, as hormones may not always be the cause.

Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.

Sex hormones do not cause oral lichen planus.

The severity of female pattern hair loss is linked to how long someone has had it, not to levels of certain nutrients or hormones.

A protein combining parathyroid hormone and collagen helped hair regrow in mice with a hair loss condition.

Beta-caryophyllene helps improve wound healing in mice, especially in females.

Red Ginseng Extract may help human hair grow by activating growth pathways and blocking negative effects of certain hormones.

Careful medical care is needed for those over 50 on hormone therapy during COVID-19.

The document concludes that sex hormones and related compounds have various effects on health, with both potential benefits and risks.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Finasteride, a hair loss drug, may cause long-term sexual side effects due to changes in hormone receptor levels.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.